menu

CME: COVID-19 & Cardiovascular Considerations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

COVID-19 & Cardiovascular Considerations

close
0.25 credits
15 Minutes
COVID-19 & Cardiovascular Considerations
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Tune in as Drs. C. Michael Gibson and Deepak Bhatt from the Harvard Medical School discuss their experiences managing patients with cardiovascular disease during the COVID-19 pandemic along with the evidence that’s been accumulated about the interplay between COVID-19 and cardiovascular disease.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
    Executive Director of Interventional Cardiovascular Programs,
    Brigham and Women’s Hospital Heart & Vascular Center
    Professor of Medicine, Harvard Medical School
    Boston, MA 

    Contracted Research: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company 

    C. Michael Gibson, MD, MS
    Interventional Cardiologist
    Professor of Medicine
    Harvard Medical School
    Boston, MA

    Consulting Fees: Amarin Pharama, Amgen, Angel Medical Corporation, AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Caladrius Biosciences Cardiovascular Research Foundation, CeleCor Therapeutics, CSL Behring, Chiesi, Duke Clinical Research Institute, Eidos Therapeutics, Eli Lilly and Company, GE Healthcare, Gilead Sciences, Inc., Impact Bio LTD, Janssen Pharmaceuticals, Johnson & Johnson Corporation, The Medicines Company, MedImmune, Medtelligence, Merck & Co., Inc., Microport, Microdrop, LLC, Novo Nordisk, PERT Consortium, Pharma Mar, Thrombolytic Science, Sanofi, Somahlution, Vereseon Corporation, Web MD
    Research/Grant Funding: Angel Medical Corporation, CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corporation, SCAD Alliance
    Equity: nference
    Royalties: UpToDate in Cardiovascular Medicine

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the increased risk of patients with CVD who are COVID-19+
    • Describe cardiovascular complications associated with therapies used for the treatment of COVID-19
  • Target Audience

    This activity is designed to meet the educational needs of Primary Care, Emergency Medicine, Cardiology, Internal Medicine, and ICU Physicians, NPs/PAs, and Nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity has no commercial support.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Tune in as Drs. C. Michael Gibson and Deepak Bhatt from the Harvard Medical School discuss their experiences managing patients with cardiovascular disease during the COVID-19 pandemic along with the evidence that’s been accumulated about the interplay between COVID-19 and cardiovascular disease.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
    Executive Director of Interventional Cardiovascular Programs,
    Brigham and Women’s Hospital Heart & Vascular Center
    Professor of Medicine, Harvard Medical School
    Boston, MA 

    Contracted Research: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company 

    C. Michael Gibson, MD, MS
    Interventional Cardiologist
    Professor of Medicine
    Harvard Medical School
    Boston, MA

    Consulting Fees: Amarin Pharama, Amgen, Angel Medical Corporation, AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Caladrius Biosciences Cardiovascular Research Foundation, CeleCor Therapeutics, CSL Behring, Chiesi, Duke Clinical Research Institute, Eidos Therapeutics, Eli Lilly and Company, GE Healthcare, Gilead Sciences, Inc., Impact Bio LTD, Janssen Pharmaceuticals, Johnson & Johnson Corporation, The Medicines Company, MedImmune, Medtelligence, Merck & Co., Inc., Microport, Microdrop, LLC, Novo Nordisk, PERT Consortium, Pharma Mar, Thrombolytic Science, Sanofi, Somahlution, Vereseon Corporation, Web MD
    Research/Grant Funding: Angel Medical Corporation, CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corporation, SCAD Alliance
    Equity: nference
    Royalties: UpToDate in Cardiovascular Medicine

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the increased risk of patients with CVD who are COVID-19+
    • Describe cardiovascular complications associated with therapies used for the treatment of COVID-19
  • Target Audience

    This activity is designed to meet the educational needs of Primary Care, Emergency Medicine, Cardiology, Internal Medicine, and ICU Physicians, NPs/PAs, and Nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity has no commercial support.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/30/20